AboutFace: A randomized controlled evaluation of an online peer-based intervention to increase PTSD treatment engagement.

Psychol ServNov 6, 2025 (epub)
Clinical ResearchPsychiatry

Anouk L Grubaugh, Tatiana Davidson, Ken Ruggiero et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated AboutFace, an online peer-based intervention, against a psychoeducational brochure in 330 veterans referred for PTSD treatment after a specialty-clinic intake. Participants were assessed for treatment engagement and related outcomes at baseline and 1, 3, and 6 months. In intention-to-treat analyses, the groups did not differ significantly. In secondary as-treated analyses, veterans who accessed AboutFace for at least 15 min were more likely to initiate treatment, did so sooner, and completed more therapy sessions than those who did not access it. The authors describe the findings as supporting potential benefit for treatment initiation.

Key findings

  • Among all randomized participants, intention-to-treat analyses found no statistically significant group differences in outcomes.
  • In as-treated analyses, participants accessing AboutFace for at least 15 min were more likely to initiate PTSD treatment, initiated sooner, and completed more therapy sessions.

Why it matters

Low engagement can limit the reach of available evidence-based PTSD care. The trial suggests that an accessible, peer-based online resource may help some veterans move from referral toward treatment, while the absence of intention-to-treat differences means the overall effectiveness of offering the intervention remains uncertain.

What to keep in mind

A large percentage of participants assigned to AboutFace did not comply with the intervention, and the positive findings came from as-treated rather than intention-to-treat analyses.

Source

Published in Psychol Serv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.